17 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for plecanatide for irritable bowel syndrome with constipation has been accepted by Health Canada. 

Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as Trulance in the U.S.) from Synergy Pharmaceuticals in February 2018.

Trulance is a once daily tablet approved by the U.S. FDA for the treatment of adults with irritable bowel syndrome with constipation.

Read Cipher Pharmaceuticals press release